SCHEMBL4068595

SCHEMBL4068595

CCC(CC)N1CCC2(CCN(CCCn3ccnc3CN(C)Cc3nc4ccccc4[nH]3)C2)CC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.35
OPRM1 P35372 1/20 0.35
OPRL1 P41146 1/20 0.35
CXCR4 P61073 3/20 0.35
CYP3A4 P08684 2/20 0.35
DRD4 P21917 9/20 0.35
DRD2 P14416 3/20 0.35
DRD3 P35462 2/20 0.35
HTR1A P08908 1/20 0.35
HTR7 P34969 1/20 0.35
HRH1 P35367 1/20 0.35
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
ALOX15 P16050 1/20 0.33
OPRK1 P41145 1/20 0.33
SIGMAR1 Q99720 1/20 0.33
LMNA P02545 1/20 0.33
TSHR P16473 1/20 0.33
ERN1 O75460 1/20 0.32
PON1 P27169 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4077923 0.89 CXCR4 (0.39) TDP1OPRM1OPRL1CXCR4CYP3A4
SCHEMBL4073717 0.85 TDP1 (0.41) TDP1OPRM1OPRL1HRH1ALDH1A1
SCHEMBL4069578 0.78 CXCR4 (0.42) OPRM1OPRL1CXCR4SIGMAR1LMNA
SCHEMBL4067101 0.76 TDP1 (0.41) TDP1OPRM1OPRL1CXCR4CYP3A4
SCHEMBL4528221 0.74 OPRM1 (0.44) OPRM1OPRL1CYP3A4DRD3ALDH1A1
SCHEMBL4067003 0.74 OPRM1 (0.43) OPRM1OPRL1CXCR4CYP3A4ALDH1A1
SCHEMBL4074607 0.74 CXCR4 (0.38) OPRM1OPRL1CXCR4
SCHEMBL4067735 0.73 CXCR4 (0.52) OPRM1OPRL1CXCR4CYP3A4HRH1
SCHEMBL4074612 0.73 CXCR4 (0.38) OPRM1OPRL1CXCR4
SCHEMBL4072227 0.72 CXCR4 (0.42) CXCR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090325992-A1 COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
US-20090325992-A1 COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
US-20090325992-A1 COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
EP-2055705-A1 COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF Ono Pharmaceutical CO., LTD. (JP) 2009-05-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325992-A1 COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF CXCR4, CXCL12, CXCR1 TDP1 3896/4885OPRM1 1350/4885OPRL1 397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.